• Home
  • News
  • Fortune 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
MPWTheranos

Theranos Is Looking For a New Lab Director in California

By
Valentina Zarya
Valentina Zarya
Down Arrow Button Icon
By
Valentina Zarya
Valentina Zarya
Down Arrow Button Icon
November 6, 2015, 11:34 AM ET
Fortune Global Forum 2015
FORTUNE GLOBAL FORUM Monday, November 2nd, 2015 2015 FORTUNE GLOBAL FORUM San Fransisco, CA, USA Elizabeth Holmes, Theranos founder and CEO Panelists: Elizabeth Holmes Fortune Editor Alan Murray Photograph by Stuart Isett/Fortune Global ForumPhotograph by Stuart Isett/Fortune Global Foru

Blood testing company Theranos is looking to hire a new director for its Newark, Calif., laboratory, according to The Wall Street Journal.

According to the Journal‘s sources, the company has advertised the position on its website and has approached directors of other labs in California.

The lab’s current director is Sunil Dhawan, a dermatologist with no background in laboratory science. Technically, since Dr. Dhawan is a medical doctor and has experience supervising a lab (Theranos said he has overseen the lab affiliated with his dermatology practice for two decades), Dr. Dhawan meets federal and state requirements to lead a lab. However, a dermatologist is an odd choice for lab director of a blood-testing company.

“When you consider the complexities of a reference lab [that performs a wide range of blood tests], it would be next-to-unheard of to have anything less than a full-time pathologist or laboratory scientist with a Ph.D. as the laboratory director,” Ed Thornborrow, medical director of the clinical labs at the University of California, San Francisco told the paper.


The company has also made moves to restructure its board, which has also been criticized for its lack of medical expertise.

These changes come after the Journalpublished an expose last month that accused the company of not using its own technology to conduct most of its blood tests, questioned the accuracy of its lab results, and suggested that the company had cheated on proficiency tests.

Theranos CEO and founder Elizabeth Holmes has since vehemently denied many of the publication’s claims, saying that the company hasn’t been using its technology due to the FDA approval process.

“Right now, just because of this FDA transition,” she said, “we are only doing one, but that doesn’t mean we don’t have the technology to do them. There’s no reason we can’t do peer review and publish other statistics.” Holmes told Fortune editor Alan Murray at FortuneGlobal Forum earlier this week.

For a full timeline of the Theranos saga, click here.

About the Author
By Valentina Zarya
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.